DNA Script SAS is closing a $200 million series C fundraising round, with new investors pumping in cash to push commercialization of its DNA printing platform Syntax. The company has raised a total of $315 million to date following the launch of the automated benchtop nucleic acid printer in June 2021. European venture firm Eurekare joined the second tranche alongside T. Rowe Price Associates and Baillie Gifford, Healthcor Management, Irving Investors and Sino Biopharmaceutical.

Sirnaomics Ltd. became the first RNA therapeutics company to list on the Hong Kong Stock Exchange (HKEX) with a $64 million initial public offering. Its shares (HKEX:2277) have since surged, rising to HK$93.90 ($12.04) on Jan. 4 following their debut at HK$65.90 per share.

LONDON – Novo Holdings has inspired the formation of the second new fund in 18 months aiming to feed more capital into the commercialization of Scandinavian science, acting as cornerstone investor in Sound Bioventures Fund I. The new fund greeted the New Year with a first close of €110 million (US$124 million), to be invested in private biopharmas with late preclinical or clinical programs, primarily in rare diseases.

The need to develop advanced medical technologies is ever increasing, and one incubator is on a mission to identify the world’s most promising opportunities. In cooperation with partners including Israel Innovation Authority, Israeli incubator Medx Xelerator LP is expanding a portfolio of startups that are attacking some of health care’s biggest challenges.